These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 32535161

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A treatment planning study comparing IMRT techniques and cyber knife for stereotactic body radiotherapy of low-risk prostate carcinoma.
    Scobioala S, Kittel C, Elsayad K, Kroeger K, Oertel M, Samhouri L, Haverkamp U, Eich HT.
    Radiat Oncol; 2019 Aug 09; 14(1):143. PubMed ID: 31399115
    [Abstract] [Full Text] [Related]

  • 6. Volumetric-modulated arc stereotactic body radiotherapy for prostate cancer: dosimetric impact of an increased near-maximum target dose and of a rectal spacer.
    Ruggieri R, Naccarato S, Stavrev P, Stavreva N, Fersino S, Giaj Levra N, Mazzola R, Mancosu P, Scorsetti M, Alongi F.
    Br J Radiol; 2015 Oct 09; 88(1054):20140736. PubMed ID: 26235142
    [Abstract] [Full Text] [Related]

  • 7. Assessing the role of volumetric modulated arc therapy (VMAT) relative to IMRT and helical tomotherapy in the management of localized, locally advanced, and post-operative prostate cancer.
    Davidson MT, Blake SJ, Batchelar DL, Cheung P, Mah K.
    Int J Radiat Oncol Biol Phys; 2011 Aug 01; 80(5):1550-8. PubMed ID: 21543164
    [Abstract] [Full Text] [Related]

  • 8. Dosimetric feasibility of stereotactic irradiation of primary prostate cancer at 5x9 Gy with a method of urethral sparing.
    Benhmida S, Beneux A, Udrescu C, Rouviere O, Horn S, Enachescu C, Lapierre A, Chapet O.
    Br J Radiol; 2021 Nov 01; 94(1127):20210142. PubMed ID: 34283647
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Use of EORTC target definition guidelines for dose-intensified salvage radiation therapy for recurrent prostate cancer: results of the quality assurance program of the randomized trial SAKK 09/10.
    Sassowsky M, Gut P, Hölscher T, Hildebrandt G, Müller AC, Najafi Y, Kohler G, Kranzbühler H, Guckenberger M, Zwahlen DR, Azinwi NC, Plasswilm L, Takacs I, Reuter C, Sumila M, Manser P, Ost P, Böhmer D, Pilop C, Aebersold DM, Ghadjar P.
    Int J Radiat Oncol Biol Phys; 2013 Nov 01; 87(3):534-41. PubMed ID: 23972722
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A treatment planning and acute toxicity comparison of two pelvic nodal volume delineation techniques and delivery comparison of intensity-modulated radiotherapy versus volumetric modulated arc therapy for hypofractionated high-risk prostate cancer radiotherapy.
    Myrehaug S, Chan G, Craig T, Weinberg V, Cheng C, Roach M, Cheung P, Sahgal A.
    Int J Radiat Oncol Biol Phys; 2012 Mar 15; 82(4):e657-62. PubMed ID: 22245189
    [Abstract] [Full Text] [Related]

  • 15. Dosimetric benefits of hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy.
    Kishan AU, Park SJ, King CR, Roberts K, Kupelian PA, Steinberg ML, Kamrava M.
    Br J Radiol; 2015 Mar 15; 88(1056):20150658. PubMed ID: 26463234
    [Abstract] [Full Text] [Related]

  • 16. Dosimetric and radiobiological impact of intensity modulated proton therapy and RapidArc planning for high-risk prostate cancer with seminal vesicles.
    Rana S, Cheng C, Zhao L, Park S, Larson G, Vargas C, Dunn M, Zheng Y.
    J Med Radiat Sci; 2017 Mar 15; 64(1):18-24. PubMed ID: 27741379
    [Abstract] [Full Text] [Related]

  • 17. Volumetric modulated arc therapy treatment planning of thoracic vertebral metastases using stereotactic body radiotherapy.
    Mallory M, Pokhrel D, Badkul R, Jiang H, Lominska C, Wang F.
    J Appl Clin Med Phys; 2018 Mar 15; 19(2):54-61. PubMed ID: 29349867
    [Abstract] [Full Text] [Related]

  • 18. Treatment planning comparison of IMPT, VMAT and 4π radiotherapy for prostate cases.
    Tran A, Zhang J, Woods K, Yu V, Nguyen D, Gustafson G, Rosen L, Sheng K.
    Radiat Oncol; 2017 Jan 11; 12(1):10. PubMed ID: 28077128
    [Abstract] [Full Text] [Related]

  • 19. Relationship between pelvic organ-at-risk dose and clinical target volume in postprostatectomy patients receiving intensity-modulated radiotherapy.
    Stanic S, Mathai M, Cui J, Purdy JA, Valicenti RK.
    Int J Radiat Oncol Biol Phys; 2012 Apr 01; 82(5):1897-902. PubMed ID: 21536391
    [Abstract] [Full Text] [Related]

  • 20. Target miss using PTV-based IMRT compared to robust optimization via coverage probability concept in prostate cancer.
    Outaggarts Z, Wegener D, Berger B, Zips D, Paulsen F, Bleif M, Thorwarth D, Alber M, Dohm O, Müller AC.
    Acta Oncol; 2020 Aug 01; 59(8):911-917. PubMed ID: 32436467
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.